Adjuvante Therapie des kolorektalen Karzinoms: Vom Kaffee über Azetylsalizylsäure bis Chemotherapie
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
Adjuvant treatment should be considered in all patients with newly diagnosed resectable colon cancer stage II and III. Clinical and histopathological criteria are relevant for identifying patients who will most likely benefit from systemic treatment. Nowadays, defective mismatch repair or high microsatellite instability (MSI-H) should be tested before considering chemotherapy in stage II colon cancer. Targeted immune-oncologic therapies and predictive molecular markers, such as circulating tumor DNA (ctDNA), are currently being evaluated in clinical trials. The number of older patients with cancer will considerably increase over the next few years and will require greater attention in clinical trials and guidelines.
Details
Translated title of the contribution | Adjuvant therapy of colorectal cancer From coffee to acetylsalicylic acid to chemotherapy |
---|
Original language | German |
---|---|
Pages (from-to) | 290-299 |
Number of pages | 10 |
Journal | Gastroenterologe |
Volume | 15 |
Issue number | 4 |
Publication status | Published - 1 Jul 2020 |
Peer-reviewed | Yes |
External IDs
ORCID | /0000-0002-9321-9911/work/142251980 |
---|
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- Colon cancer, Microsatellite instability, Mismatch repair deficiency, Neoadjuvant therapy, Targeted molecular therapy